18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- 3 year progression-free survival
研究概览
简要总结
The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of NK/T-cell lymphoma can predict disease progression
详细描述
In this study investigators develop a prognostic model based on 18F-FDG PET/CT and test its ability for prognostic value in patients with DLBCL. PET/ CT scans evaluation using the liver SUVmax as reference. Positive lesions in PET were indicated as SUVmax of residues higher than the threshold or new 18F-FDG avid lesions. 18F-FDG PET/CT-based prognostic model includes PET/CT image, dominant clinical and pathological prognostic factors to predicting disease progression during chemotherapy or survival in NK/T-cell lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 80 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •newly diagnosed NK/T-cell lymphoma
- •treated using an anthracycline-containing regimen
- •minimal follow-up at 6 months after the completion of first-line treatment
- •complete medical history and clinicopathological data
排除标准
- •secondary malignant disease
- •serious infection or inflammation (e.g., HIV)
- •primary central nervous system lymphoma
- •hepatic or renal dysfunction.
结局指标
主要结局
3 year progression-free survival
时间窗: up to 3 years after initial diagnosis
次要结局
未报告次要终点
研究者
Xuejuan Wang,MD
Principal Investigator
Peking University Cancer Hospital & Institute